Skip to main navigation Skip to search Skip to main content

Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich’s Ataxia

  • Theresa A. Zesiewicz
  • , Kelly L. Sullivan
  • , J. Farmer
  • , C. Kamp
  • , R. Chen
  • , A. Brocht
  • , S. Bennett
  • , Israt Jahan
  • , Clifton L. Gooch
  • , Amber M. Miller
  • , David R. Lynch
  • University of South Florida

Research output: Contribution to book or proceedingChapter

Abstract

This conference abstract was published in the Proceedings of the American Academy of Neurology Annual Meeting.
Original languageAmerican English
Title of host publicationProceedings of the American Academy of Neurology Annual Meeting
StatePublished - Apr 13 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Disciplines

  • Epidemiology
  • Public Health

Keywords

  • Chantix®
  • Double-blind
  • Friedreich's Ataxia
  • Pilot study
  • Placebo-controlled
  • Randomized
  • Treatment
  • Varenicline

Fingerprint

Dive into the research topics of 'Double-Blind, Randomized, Placebo-Controlled Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich’s Ataxia'. Together they form a unique fingerprint.

Cite this